Molnupiravir for COVID-19 disease -

molnupiravir dose  The probability of ≥30% excess toxicity over controls at 800 mg was estimated at % Conclusions Molnupiravir was safe and well tolerated; a dose of 800 mg Someone who stops breastfeeding in order to take molnupiravir may resume four days after receiving their last dose of the drug This gives the body enough time

68% of patients in the molnupiravir group had received at least three doses of mRNA vaccine or two doses of the S vaccine during treatment with molnupiravir and for 4 days after the last dose of molnupiravir • Do not double the dose of molnupiravir to make up for a missed dose

Two oral drugs, molnupiravir and paxlovid , provide equivalent therapeutic benefit in preventing severe COVID-19 in Adults: The recommended dose of MOLNUPAC is 800 mg taken orally every 12 hours for 5 days The safety and efficacy